Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BCL2 expression + MYC expression
i
Other names:
MYC, bHLHe39, c-Myc, MYCC, V-myc avian myelocytomatosis viral oncogene homolog, BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4609
;
596
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
MYC-IGH fusion (3)
IL7R-BCL2 fusion (1)
MYC-BCL2 fusion (0)
BCL2 fusion (0)
MYC-IGH fusion (3)
IL7R-BCL2 fusion (1)
MYC-BCL2 fusion (0)
BCL2 fusion (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
chidamide
Sensitive: A1 - Approval
chidamide
Sensitive
:
A1
chidamide
Sensitive: A1 - Approval
chidamide
Sensitive
:
A1
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
methotrexate
Resistant: C3 – Early Trials
methotrexate
Resistant
:
C3
methotrexate
Resistant: C3 – Early Trials
methotrexate
Resistant
:
C3
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
cytarabine + methotrexate
Resistant: C3 – Early Trials
cytarabine + methotrexate
Resistant
:
C3
cytarabine + methotrexate
Resistant: C3 – Early Trials
cytarabine + methotrexate
Resistant
:
C3
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
R-CHOP
Resistant: C3 – Early Trials
R-CHOP
Resistant
:
C3
R-CHOP
Resistant: C3 – Early Trials
R-CHOP
Resistant
:
C3
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
lenalidomide + zanubrutinib
Sensitive: C3 – Early Trials
lenalidomide + zanubrutinib
Sensitive
:
C3
lenalidomide + zanubrutinib
Sensitive: C3 – Early Trials
lenalidomide + zanubrutinib
Sensitive
:
C3
BCL2 expression + MYC expression
Lymphoma
BCL2 expression + MYC expression
Lymphoma
methotrexate
Resistant: C3 – Early Trials
methotrexate
Resistant
:
C3
methotrexate
Resistant: C3 – Early Trials
methotrexate
Resistant
:
C3
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
orelabrutinib
Sensitive: C3 – Early Trials
orelabrutinib
Sensitive
:
C3
orelabrutinib
Sensitive: C3 – Early Trials
orelabrutinib
Sensitive
:
C3
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
CD20-targeted CAR-T immunotherapy + venetoclax
Sensitive: D – Preclinical
CD20-targeted CAR-T immunotherapy + venetoclax
Sensitive
:
D
CD20-targeted CAR-T immunotherapy + venetoclax
Sensitive: D – Preclinical
CD20-targeted CAR-T immunotherapy + venetoclax
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login